Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Eur J Gynaecol Oncol ; 30(3): 292-4, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19697624

RESUMEN

PURPOSE: Multiple clinical trials in recent years have shown that breast cancer patients with primary tumors overexpressing ERBB2 can be effectively treated with specific forms of modern anti-ERBB2-targeted therapy. The aim of the present study was to analyze the expression of the ERBB2 (HER2) protein in uterine sarcomas, in order to investigate the possibility of applying this treatment modality in uterine sarcomas. METHODS: The expression of ERBB2 has been analyzed immunohistochemically in formalin-fixed paraffin-embedded primary uterine sarcomas (n = 11). RESULTS: Using a semi-quantitative immunohistochemical score, we found that ERBB2 expression was very weak in the majority of tumors, with only three sarcomas showing moderate ERBB2 expression. Published studies evaluating the same issue in small numbers of uterine sarcomas reached similar findings. CONCLUSION: Overall, ERBB2 expression appears to be weak in uterine sarcomas. However, targeted treatment might still be feasible in a subgroup of patients with uterine sarcomas overexpressing ERBB2.


Asunto(s)
Receptor ErbB-2/metabolismo , Sarcoma/metabolismo , Neoplasias Uterinas/metabolismo , Adulto , Anciano , Femenino , Humanos , Inmunohistoquímica , Leiomiosarcoma/metabolismo , Persona de Mediana Edad , Sarcoma/tratamiento farmacológico , Neoplasias Uterinas/tratamiento farmacológico
2.
Eur J Gynaecol Oncol ; 30(3): 338-40, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19697637

RESUMEN

Ovarian hilus or Leydig cell tumor and ovarian hilus cell hyperplasia are rare clinical entities, causing virilization in both pre- and postmenopausal women. Differentiation between these two conditions is not always straightforward; the former is usually unilateral appearing as a single, grossly visible, circumscribed mass of hilus cells, while the latter is usually bilateral, appearing as diffuse microscopic aggregates of hilus cells. We report herein an extremely rare case of ovarian hilus or Leydig cell tumor, presenting concurrently with contralateral ovarian hilus cell hyperplasia in a postmenopausal woman with virilization. To the best of our knowledge, only four such cases have been previously reported in the literature. Ovarian hilus cell tumors and hilus hyperplasia almost always have benign biological behavior, thus making bilateral salpingo-oophorectomy an appropriate and sufficient therapeutic approach.


Asunto(s)
Tumor de Células de Leydig/patología , Neoplasias Ováricas/patología , Virilismo/etiología , Femenino , Humanos , Hiperplasia , Tumor de Células de Leydig/complicaciones , Persona de Mediana Edad , Neoplasias Ováricas/complicaciones
3.
Eur J Gynaecol Oncol ; 30(2): 239-40, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19480269

RESUMEN

Metastatic tumors to the uterine cervix originating from malignancies in other organs are very rare. A case of a 45-year-old white woman presenting with vaginal bleeding, due to renal cell carcinoma metastasizing to the cervix, is reported. The patient had been treated four years and five months earlier due to two primary malignancies: colon adenocarcinoma and renal cell carcinoma. After D&C, microscopic examination and immunohistochemical staining showed that the tumor was metastatic, originating from the renal cell carcinoma. Radical hysterectomy with bilateral salpingo-oophorectomy and pelvic lymph node resection followed, and postoperatively the patient received targeted therapy with sutinib malate. The possibility of metastasis from another primary should be considered in the differential diagnosis of tumors of the uterine cervix in order to plan optimal management.


Asunto(s)
Carcinoma de Células Renales/secundario , Neoplasias Renales/patología , Neoplasias del Cuello Uterino/secundario , Carcinoma de Células Renales/patología , Carcinoma de Células Renales/terapia , Femenino , Humanos , Persona de Mediana Edad , Neoplasias del Cuello Uterino/patología , Neoplasias del Cuello Uterino/terapia
4.
Artículo en Inglés | MEDLINE | ID: mdl-19104743

RESUMEN

T-cell-rich B-cell lymphoma (TCRBCL) is a recently recognized B-cell lymphoma variant, characterized by a minor population of neoplastic B-cells existing in a background of predominant reactive T-lymphocytes. It is a rare entity, accounting for approximately 1 to 2% of all non-Hodgkin's lymphomas. It has both nodal and extranodal presentation. Primary cutaneous TCRBCL is an extremely rare lymphoma and only 16 cases have been documented thus far in the medical literature. We report the case of a 46- year-old man that presented with a slowly-growing, painless skin nodule on the left temporofrontal region of the scalp. A complete surgical excision was performed and histological examination revealed diffuse infiltration of the dermis by TCRBCL. A complete surgical excision of the skin lesion and systemic chemotherapy seems to have been effective because the patient is disease-free 2 years after the initial diagnosis was made. This study reports a very rare case of TCRBCL presented primarily in the skin. Because of its rarity, it is especially important to make the correct diagnosis using the appropriate immunohistochemical stains and apply the proper therapy.


Asunto(s)
Neoplasias de Cabeza y Cuello/patología , Linfoma de Células B/patología , Cuero Cabelludo/patología , Neoplasias Cutáneas/patología , Linfocitos T/patología , Humanos , Masculino , Persona de Mediana Edad
5.
Eur J Gynaecol Oncol ; 29(3): 264-6, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-18592792

RESUMEN

PURPOSE: The aim of the present study was to investigate the possibility of treating uterine sarcomas with imatinib mesylate. Imatinib mesylate, a selective tyrosine kinase inhibitor, is very efficient against mesenchymal tumors of the gastrointestinal tract, known as GISTs. Imatinib mesylate acts against a tyrosine kinase encoded by the KIT gene in GISTs, and is more effective in tumors expressing this protein. METHODS: Expression of KIT was analyzed immunohistochemically (n = 12) in formalin-fixed paraffin-embedded primary uterine sarcomas. RESULTS: Using a semi-quantitative immunohistochemical score we found that KIT expression was very weak in the majority of tumors, while none of the uterine sarcomas tested showed strong expression. Overall, published studies addressing this issue in small series of uterine sarcomas yielded similar results. CONCLUSION: Current data suggest that it is unlikely that imatinib mesylate could be used effectively as a single agent in patients with uterine sarcomas.


Asunto(s)
Neoplasias Endometriales/metabolismo , Leiomiosarcoma/metabolismo , Proteínas Proto-Oncogénicas c-kit/metabolismo , Sarcoma Estromático Endometrial/metabolismo , Benzamidas , Femenino , Humanos , Mesilato de Imatinib , Inmunohistoquímica , Piperazinas/uso terapéutico , Inhibidores de Proteínas Quinasas/uso terapéutico , Pirimidinas/uso terapéutico , Sarcoma Estromático Endometrial/genética , Sarcoma Estromático Endometrial/patología
6.
Rev Esp Enferm Dig ; 99(3): 145-8, 2007 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-17516827

RESUMEN

Composite neoplasms, carcinoid and adenocarcinoma have been reported to occur in several parts of the body, including the stomach, ampulla of Vater, large bowel, lung, and urinary bladder. Here we report a case of a 74-year-old male with a composite carcinoid-adenocarcinoma of the ileum associated with a transitional cell carcinoma of the bladder. The microscopical examination of the composite tumor showed an admixture of typical carcinoid tumor and moderately a differentiated adenocarcinoma. Immunohistochemically, the two components showed clear-cut differentiations. A review of the literature revealed that this is the first reported case of composite carcinoid-adenocarcinoma of the ileum associated with transitional cell carcinoma of the urinary bladder.


Asunto(s)
Adenocarcinoma/patología , Tumor Carcinoide/patología , Carcinoma de Células Transicionales/patología , Neoplasias del Íleon/patología , Neoplasias de la Vejiga Urinaria/patología , Adenocarcinoma/complicaciones , Adenocarcinoma/cirugía , Anciano , Tumor Carcinoide/complicaciones , Tumor Carcinoide/cirugía , Carcinoma de Células Transicionales/complicaciones , Carcinoma de Células Transicionales/cirugía , Humanos , Neoplasias del Íleon/complicaciones , Neoplasias del Íleon/cirugía , Masculino , Neoplasias de la Vejiga Urinaria/complicaciones , Neoplasias de la Vejiga Urinaria/cirugía
7.
Eur J Gynaecol Oncol ; 25(3): 384-6, 2004.
Artículo en Inglés | MEDLINE | ID: mdl-15171326

RESUMEN

Primitive neuroectodermal tumors (PNETs) of the uterus are very rare. The histogenesis of these tumors is still unknown and the differential diagnosis includes a wide variety of tumor entities. We describe a rare case of a 68-year-old female who presented with persistent vaginal bleeding. Physical examination and CT-scan revealed a large tumor in the uterus. Macroscopically the tumor involved the uterine isthmus. Histological and immunohistochemical examination showed that the tumor fulfilled the diagnostic criteria set for PNET. Only a very small number of cases of PNETs of the uterus have been reported in the literature, thus no definitive conclusions concerning the therapeutic management and prognosis have been ascertained.


Asunto(s)
Tumores Neuroectodérmicos Primitivos/diagnóstico , Neoplasias Uterinas/diagnóstico , Anciano , Diagnóstico Diferencial , Femenino , Humanos , Inmunohistoquímica , Tumores Neuroectodérmicos Primitivos/complicaciones , Tumores Neuroectodérmicos Primitivos/diagnóstico por imagen , Tumores Neuroectodérmicos Primitivos/patología , Tumores Neuroectodérmicos Primitivos/cirugía , Radiografía , Hemorragia Uterina/etiología , Neoplasias Uterinas/complicaciones , Neoplasias Uterinas/diagnóstico por imagen , Neoplasias Uterinas/patología , Neoplasias Uterinas/cirugía
8.
Leuk Lymphoma ; 44(12): 2155-7, 2003 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-14959864

RESUMEN

The occurrence of second malignancies is an important late event following the treatment of Hodgkin's disease (HD). Occurrence of a non-Hodgkin's lymphoma (NHL) involving the uterine cervix after treatment for HD has not been previously reported. We describe a rare case of a 34-year old woman, with NHL involving the uterine cervix 7.5 years after treatment for HD. The follow-up of patients treated for HD should also include regular gynecological evaluation. In cases of abnormal findings, accurate diagnosis can only be made histologically.


Asunto(s)
Enfermedad de Hodgkin/tratamiento farmacológico , Enfermedad de Hodgkin/radioterapia , Linfoma no Hodgkin/patología , Neoplasias Primarias Secundarias/diagnóstico , Neoplasias del Cuello Uterino/diagnóstico , Neoplasias del Cuello Uterino/secundario , Adulto , Cuello del Útero/patología , Femenino , Humanos , Inmunohistoquímica , Metástasis Linfática , Linfoma/patología , Factores de Tiempo
11.
Histopathology ; 12(5): 533-40, 1988 May.
Artículo en Inglés | MEDLINE | ID: mdl-3397047

RESUMEN

Two patients with chronic intestinal pseudo-obstruction are reported, one of whom had definite systemic sclerosis while the other had certain manifestations of the disease. Biopsies of the small intestine revealed increased collagen and elastic fibres in the muscularis propria and subserosa in each case, while ganglion cells were normal. In addition, one patient had severe atrophy of the inner muscle layer and the other obvious vacuolation of the muscularis propria. Ultrastructural examination confirmed degeneration of the smooth muscle fibres. These latter features have been considered the hallmark of visceral myopathy and their finding in this patient therefore suggests that the different causes of pseudo-obstruction may not be completely demarcated and cases in which the features overlap may occur.


Asunto(s)
Seudoobstrucción Intestinal/patología , Esclerodermia Sistémica/patología , Anciano , Enfermedad Crónica , Humanos , Seudoobstrucción Intestinal/diagnóstico , Masculino , Microscopía Electrónica , Persona de Mediana Edad , Esclerodermia Sistémica/diagnóstico
12.
Histopathology ; 12(4): 451-4, 1988 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-3371900

RESUMEN

Therapeutic use of oestrogens by males with carcinoma of the prostate leads to testicular atrophy with markedly reduced spermatogenesis after only 21 d (Oshima et al. 1974). Treatment for over a year results in paucity of germ cells, vacuolation of Sertoli cells and reduction in Leydig cells (Lu & Steinberger 1978, Smith & Urry 1985). There is, apparently, no information on the histology of the human testis after more than 1 year oestrogen therapy. We here report changes in testes from five transsexuals treated for periods of up to 5.5 years.


Asunto(s)
Estrógenos/efectos adversos , Testículo/efectos de los fármacos , Adulto , Atrofia , Estrógenos/administración & dosificación , Humanos , Masculino , Persona de Mediana Edad , Células de Sertoli/efectos de los fármacos , Células de Sertoli/patología , Testículo/patología , Factores de Tiempo , Transexualidad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...